October 26, 2022
FDA: Class I recall of Jiangsu Well Biotech COVID-19 Ag Rapid Test
Editor's Note
The Food and Drug Administration (FDA) on October 12 identified the recall of Jiangsu Well Biotech’s COVID-19 Ag Rapid Test Devices as Class I, the most serious.
The recall was initiated because the tests were distributed to US customers without authorization, clearance, or approval from the FDA.
No complaints, injuries, or deaths have been reported.
Distribution dates were July 23, 2021 to January 23, 2022.
Free Daily News
- Infection control guidelines focus on regional anesthesia, pain management
- Study links high surgeon stress, positive patient outcomes
- Researchers recommend extending colonoscopy screening interval for low-risk patients
- New wrong-site surgery prevention toolkit seeing traction in ASCs
- Podcast episode discusses the anesthesia provider shortage in ASCs
- Study explores use of antibiotics as alternative to pediatric appendectomy
- Medical device shortages present pediatric patient challenges, FDA warns
- Expansive study highlights GLP-1 risks, potential beyond weight loss, diabetes treatment
- HHS report highlights cost, access, quality concerns with private equity in healthcare
- Study: Racial, gender disparities persist in bariatric surgery
© Access Intelligence, LLC. All rights reserved. |
Privacy Policy |
Cookie Settings |
Diversity, Equity, Inclusion & Belonging |
Accessibility Statement